Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics

NCT02304159 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C
Cirrhosis

Interventions

DRUG: daclatasvir
DRUG: Sofosbuvir, Sovaldi
DRUG: Ribavirin

Sponsor

Tarek I. Hassanein, M.D., FACP, FAG, AGAF